Skip to main content
Have a personal or library account? Click to login
The Effect of Mask Use on Seasonal Virus Diversity in SARS CoV-2 Negative Patients Treated as Inpatients During the 2021–2022 and 2022–2023 Seasonal Flu Period Cover

The Effect of Mask Use on Seasonal Virus Diversity in SARS CoV-2 Negative Patients Treated as Inpatients During the 2021–2022 and 2022–2023 Seasonal Flu Period

Open Access
|Sep 2024

Figures & Tables

graphic/j_pjm-2024-033_fig_001.jpg
Table I

Demographic features of the patients.

Age (Mean ± SD)66.4 ± 13.6
Gender (n, %)
Male852 (63.8%)
Female483 (36.2%)
Comorbidity (n, %)
Hypertension787 (59%)
COPD714 (53.2%)
IHD467 (35%)
Asthma323 (24.2%)
CVD173 (13%)
Malignancy87 (6.5%)
Bronchiectasis66 (4.9%)
CRF49 (3.7%)
Alzheimer33 (2.5%)
Diabetes28 (2.1%)
DILD18 (1.3%)
Hospitalization diagnoses (n, %)
COPD exacerbation645 (48.3%)
Pneumonia435 (32.6%)
Asthma attack255 (19.1%)

1 COPD – chronic obstructive pulmonary disease,

1 IHD – ischemic heart disease, CVD – cerebrovascular disease,

1 CRF – chronic renal failure, DILD – diffuse interstitial lung disease

Table II

Viral and Mycoplasma panel PCR results by hospitalization diagnoses.

COPD n (%)Pneumonia n (%)Asthma n (%)
Influenza A72 (11.2)47 (10.8)31 (12.2)
H1N161 (9.5)39 (9)25 (9.8)
H3N252 (8.1)25 (5.7)22 (8.6)
Influenza B3 (0.5)4 (0.9)3 (1.2)
Other Respiratory Viruses98 (15.2)68 (15.6)56 (22)
Adenovirus5 (0.8)4 (0.9)1 (0.4)
Human coronavirus26 (4)17 (3.9)14 (5.5)
Parainfluenzavirus 1–48 (1.2)2 (0.5)7 (2.7)
Entero/Rhinovirus34 (5.3)26 (6)19 (7.5)
Human bocavirus1 (0.2)02 (0.8)
Human metapneumovirus3 (0.5)3 (0.7)5 (2)
RSV/EU22 (3.4)16 (3.7)9 (3.5)
Parecohvirus000
Bacteria000
Mycoplasma spp.000

1 COPD – chronic obstructive pulmonary disease,

1 RSV – respiratory syncytial virus

Fig. 1.

Viral panel PCR results in the first and second periods.

Table III

Viral and Mycoplasma panel PCR results in the first and second periods.

First period (n = 424) n (%)Second period (n = 911) n (%)p-value
Influenza A35 (8.3)115 (12.6)0.019
H1N125 (5.9)100 (11)0.003
H3N233 (7.8)66 (7.2)0.72
Influenza B1 (0.2)9 (1)0.13
Other Respiratory Tract Viruses68 (16)222 (116.6)0.69
Adenovirus2 (0.5)8 (0.9)0.42
Human Coronavirus19 (4.5)38 (4.2)0.78
Coronavirus HKU14 (0.9)00.003
Coronavirus 229E6 (1.4)00.000
Coronavirus NL631 (0.2)3 (0.3)0.77
Coronavirus OC4312 (2.8)37 (4.1)0.26
Parainfluenzavirus1–410 (2.4)7 (0.7)0.016
Parainfluenzavirus 101 (0.1)0.49
Parainfluenzavirus 24 (0.9)00.03
Parainfluenzavirus 31 (0.2)7 (0.8)0.24
Parainfluenzavirus 46 (1.4)1 (0.1)0.02
Entero/Rhinovirus26 (6.1)53 (5.8)0.82
Human Bocavirus1 (0.1)2 (0.2)0.95
Human Metapneumovirus8 (1.9)3 (0.3)0.003
RSV/AB2 (0.5)45 (4.9)0.000
Parecohvirus000
Bacteria000
Mycoplasma spp.000
116 (23.4)379 (41.6)0.000
DOI: https://doi.org/10.33073/pjm-2024-033 | Journal eISSN: 2544-4646 | Journal ISSN: 1733-1331
Language: English
Page range: 377 - 382
Submitted on: May 18, 2024
Accepted on: Jul 26, 2024
Published on: Sep 13, 2024
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Savaş Gegin, Burcu Özdemir, Levent Özdemir, Esra Arslan Aksu, Ahmet Cemal Pazarli, Bahadir Yazicioğlu, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.